非小细胞肺癌新辅助化免治疗达到完全病理缓解：需要术后免疫辅助治疗

新辅助免疫联合化疗，术后继续给予免疫辅助治疗的围术期免疫治疗RCT研究，证实了围术期免疫治疗同样能让早期NSCLC患者获益。
AEGEAN[Heymach JV, 2023]
Neotorch[Lu S, 2023]
KEYNOTE-671[Wakelee H, 2023]
RATIONALE-315[Yue D，2023]
CheckMate 77T[Cascone T, 2023]




参考文献：

• Heymach JV, Harpole D, Mitsudomi T, et al. Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research, 2023,83(8_Supplement):CT005-CT005.
• Lu S, Wu L, Zhang W, et al. Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. Journal of Clinical Oncology, 2023,41(36_suppl):425126-425126.
• Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2023,389(6):491-503.
• Yue D, Wang W, Liu H, et al. LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial. Annals of Oncology, 2023,34:S1299.
• Cascone T, Awad MM, Spicer JD, et al. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology, 2023,34:S1295.
  

微信扫二维码转发分享